View Older Stories View More Recent Stories

May 3, 2021 08:11AM Regeneron (REGN) Announces ATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV and Dupixent
May 3, 2021 08:00AM ATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV™ (casirivimab with imdevimab) and Dupixent® (dupilumab)
Apr 23, 2021 04:05PM Regeneron Announces Investor Conference Presentations
Apr 23, 2021 09:59AM Regeneron (REGN) Announces New Dupixent Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years
Apr 23, 2021 09:59AM New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years
Apr 12, 2021 06:16AM Regeneron (REGN) ReportsPhase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV
Apr 12, 2021 01:15AM Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19
Apr 12, 2021 01:00AM Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab)
Apr 9, 2021 08:16AM Regeneron (REGN) Announces NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV in Outpatients at High Risk of Clinical Progression
Apr 9, 2021 08:15AM NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression
Apr 6, 2021 04:05PM Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021
Mar 31, 2021 06:35AM Regeneron (REGN) Announces NIH-sponsored Trial Finds EYLEA Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients
Mar 30, 2021 07:04PM NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients
Mar 23, 2021 06:22AM Regeneron (REGN) Phase 3 Trial Shows REGEN-COV Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Mar 23, 2021 02:00AM Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Mar 17, 2021 08:57PM Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2021 for Remarkable Research on Infinite Matching Algorithms, Machine Learning to Evaluate New Medicines and Water Filtratio
Mar 15, 2021 06:15AM Regeneron (REGN) and Sanofi (SNY) Phase 3 Trial of Libtayo Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on OS
Mar 15, 2021 02:00AM Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival           
Mar 15, 2021 02:00AM Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival
Mar 4, 2021 06:17AM Regeneron (REGN), Sanofi (SNY) announce FDA accepts Dupixent for review in children with moderate-to-severe asthma
Mar 4, 2021 01:00AM FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
Mar 4, 2021 12:59AM FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma
Mar 1, 2021 05:48AM Regeneron (REGN) Reports Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
Feb 27, 2021 06:25PM Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
Feb 26, 2021 07:11AM Cathie Wood's ARK Adds ~1.7M Shares of Twitter (TWTR), Sells Apple (AAPL), Alibaba (BABA)
Feb 26, 2021 06:47AM Regeneron (REGN) announces EMA Issues Advice on its Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
Feb 26, 2021 06:46AM EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients
Feb 25, 2021 07:25AM Regeneron (REGN) Announces IDMC Finds Clear Efficacy for REGEN-COV in Phase 3 COVID-19 Outpatient Outcomes Trial
Feb 25, 2021 07:00AM Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial
Feb 23, 2021 06:51AM Cathie Wood's ARK Bought Buys ~$200M More Tesla (TSLA) Monday on Sell-Off
Feb 22, 2021 01:00PM FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Feb 22, 2021 01:00PM FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Feb 12, 2021 04:15PM Regeneron Announces Investor Conference Presentations
Feb 12, 2021 06:46AM Regeneron (REGN) Announces Lancet Publishes Libtayo Data Showing Extended OS in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Feb 12, 2021 01:00AM The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
Feb 12, 2021 01:00AM The Lancet Publishes Libtayo® (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Feb 11, 2021 05:04PM U.S. Federal Circuit Court of Appeals Rules in Favor of Regeneron and Sanofi in Praluent® (alirocumab) Patent Litigation
Feb 11, 2021 02:01PM Regeneron (REGN) Announces FDA Approves First-in-class Evkeeza for Patients with Ultra-rare Inherited Form of High Cholesterol
Feb 11, 2021 02:00PM FDA Approves First-in-class Evkeeza™ (evinacumab-dgnb) for Patients with Ultra-rare Inherited Form of High Cholesterol
Feb 9, 2021 05:24PM Regeneron (REGN) Announces FDA Approves Libtayo as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Feb 9, 2021 05:22PM FDA Approves Libtayo® (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
Feb 9, 2021 05:15PM FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
Feb 5, 2021 06:30AM Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results
Feb 1, 2021 10:01AM Regeneron (REGN) New Dupixent Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting
Feb 1, 2021 09:59AM New Dupixent® (dupilumab) Data Showcasing Improvements Across Four Type 2 Inflammatory Diseases to be Presented at 2021 AAAAI Annual Meeting
Jan 27, 2021 07:01AM Regeneron (REGN) Antibody Cocktail Is Active Against SARS-CoV-2 UK and South Africa Variants
Jan 27, 2021 07:00AM REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa
Jan 26, 2021 07:01AM Regeneron (REGN) COVID-19 Antibody Cocktail Prevented 100% of Symptomatic Infections When Used as Passive Vaccine
Jan 26, 2021 07:00AM Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19
Jan 21, 2021 12:01PM Forty of the Nation's Most Talented Young Scientists Named Finalists in Regeneron Science Talent Search 2021
View More Recent Stories View Older Stories